64 related articles for article (PubMed ID: 34340248)
1. Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
Zanwar S; Abeykoon JP; Ansell SM; Gertz MA; Colby C; Larson D; Paludo J; He R; Warsame R; Greipp PT; King RL; Thompson CA; Witzig TE; Lacy MQ; Gonsalves W; Nowakowski GS; Dingli D; Go RS; Habermann TM; Vincent Rajkumar S; Kyle RA; Kumar S; Kapoor P
Br J Haematol; 2021 Oct; 195(2):210-216. PubMed ID: 34340248
[TBL] [Abstract][Full Text] [Related]
2. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
[TBL] [Abstract][Full Text] [Related]
3. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
Castillo JJ; D'Sa S; Lunn MP; Minnema MC; Tedeschi A; Lansigan F; Palomba ML; Varettoni M; Garcia-Sanz R; Nayak L; Lee EQ; Rinne ML; Norden AD; Ghobrial IM; Treon SP
Br J Haematol; 2016 Mar; 172(5):709-15. PubMed ID: 26686858
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Sklavenitis-Pistofidis R; Capelletti M; Liu CJ; Reidy M; Zavidij O; Huynh D; Henrick P; Savell A; Reyes K; Rivotto B; Bustoros M; Perilla-Glen A; Trippa L; Castillo JJ; Treon SP; Ghobrial IM
Blood; 2018 Dec; 132(24):2608-2612. PubMed ID: 30366921
[No Abstract] [Full Text] [Related]
6. Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-Off Droplet Digital PCR in Patients with IgM Monoclonal Gammopathies.
Markou AN; Bagratuni T; Tsakiri C; Tserpeli V; Skourti S; Mavrianou Koutsoukou N; Papadimou A; Terpos E; Kastritis E; Lianidou E; Dimopoulos MA
J Mol Diagn; 2023 Jul; 25(7):502-512. PubMed ID: 37088135
[TBL] [Abstract][Full Text] [Related]
7. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
8. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Kersten MJ; Amaador K; Minnema MC; Vos JMI; Nasserinejad K; Kap M; Kastritis E; Gavriatopoulou M; Kraan W; Chamuleau MED; Deeren D; Tick LW; Doorduijn JK; Offner F; Böhmer LH; Liu RD; Pals ST; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):40-51. PubMed ID: 34388022
[TBL] [Abstract][Full Text] [Related]
9. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP
Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802
[No Abstract] [Full Text] [Related]
10. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
Trotman J; Buske C; Tedeschi A; Matous JV; MacDonald D; Tam CS; Tournilhac O; Ma S; Treon SP; Oriol A; Ping J; Briso EM; Arango-Hisijara I; Dimopoulos MA
Clin Cancer Res; 2021 Nov; 27(21):5793-5800. PubMed ID: 34380643
[TBL] [Abstract][Full Text] [Related]
11. Watch and wait in Waldenström macroglobulinaemia: looking for who to watch carefully and who can wait without worrying. Is it that simple?
Durot E; Delmer A
Br J Haematol; 2021 Oct; 195(2):155-157. PubMed ID: 34472092
[No Abstract] [Full Text] [Related]
12. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
Martinez-Baquero D; Sakhdari A; Mo H; Kim DH; Kanagal-Shamanna R; Li S; Young KH; O'Malley DP; Dogan A; Jain P; Wang ML; McDonnell TJ; Miranda RN; Vega F; Medeiros LJ; Ok CY
Mod Pathol; 2021 Dec; 34(12):2183-2191. PubMed ID: 34376807
[TBL] [Abstract][Full Text] [Related]
13. Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.
Mishina T; Oshima-Hasegawa N; Tsukamoto S; Fukuyo M; Kageyama H; Muto T; Mimura N; Rahmutulla B; Nagai Y; Kayamori K; Hino Y; Mitsukawa S; Takeda Y; Ohwada C; Takeuchi M; Tsujimura H; Iseki T; Nakaseko C; Ikeda JI; Itami M; Yokote K; Ohara O; Kaneda A; Sakaida E
Br J Haematol; 2021 Dec; 195(5):731-742. PubMed ID: 34378195
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact.
Krzisch D; Guedes N; Boccon-Gibod C; Baron M; Bravetti C; Davi F; Armand M; Smagghe L; Caron J; Bernard OA; Susin S; Chapiro E; Leblond V; Nguyen-Khac F; Roos-Weil D;
Am J Hematol; 2021 Dec; 96(12):1569-1579. PubMed ID: 34462944
[TBL] [Abstract][Full Text] [Related]
15. Role of the Bone Marrow Niche in Supporting the Pathogenesis of Lymphoid Malignancies.
Jalali S; Ansell SM
Front Cell Dev Biol; 2021; 9():692320. PubMed ID: 34395425
[TBL] [Abstract][Full Text] [Related]
16. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Landsburg DJ; Barta SK; Ramchandren R; Batlevi C; Iyer S; Kelly K; Micallef IN; Smith SM; Stevens DA; Alvarez M; Califano A; Shen Y; Bosker G; Parker J; Soikes R; Martinez E; von Roemeling R; Martell RE; Oki Y
Br J Haematol; 2021 Oct; 195(2):201-209. PubMed ID: 34341990
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Zanwar S; Ho M; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Fonder A; Hobbs M; Hwa Y; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S
Leukemia; 2022 Mar; 36(3):873-876. PubMed ID: 34635783
[No Abstract] [Full Text] [Related]
18. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Castillo JJ; Meid K; Gustine JN; Leventoff C; White T; Flynn CA; Sarosiek S; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Branagan AR; O'Donnell E; Raje N; Yee AJ; Patterson CJ; Hunter ZR; Treon SP
Leukemia; 2022 Feb; 36(2):532-539. PubMed ID: 34531537
[TBL] [Abstract][Full Text] [Related]
19. Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage.
Sarosiek S; Castillo JJ
Drugs; 2024 Jan; 84(1):17-25. PubMed ID: 38055179
[TBL] [Abstract][Full Text] [Related]
20. Current approach to Waldenström macroglobulinemia.
Kapoor P; Rajkumar SV
Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
